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BACKGROUND: Major depression is common in older adults and is
associated with increased health care costs. Depression often remains
unrecognized in older adults, especially in primary care.
OBJECTIVE: To evaluate the cost-effectiveness of a disease manage-
ment program for major depression in elderly primary care patients
compared with usual care.
DESIGN: Economic evaluation alongside a cluster randomized-con-
trolled trial.
PARTICIPANTS: Consecutive patients of 55 years and older were
screened for depression using the Geriatric Depression Scale and the
PRIME-MD was used for diagnosis.
INTERVENTIONS: General practitioners in the intervention group re-
ceived training on how to implement the disease management program
consisting of screening, patient education, drug therapy with paroxe-
tine, and supportive contacts. General practitioners in the usual care
group were blind to the screening results. Treatment in this group was
not restricted in any way.
MEASUREMENTS: Severity of depression, recovery from depression,
and quality of life. Resource use measured over a 12-month period
using interviews and valued using standard costs.
RESULTS: Differences in clinical outcomes between the intervention
and usual care group were small and statistically insignificant. Total
costs were $2,123 in the intervention and $2,259 in the usual care
group (mean difference $136, 95% confidence interval: $1,194;
$1,110). Cost-effectiveness planes indicated that there were no statis-
tically significant differences in cost-effectiveness between the 2
groups.
CONCLUSIONS: This disease management program for major depres-
sion in elderly primary care patients had no statistically significant re-
lationship with clinical outcomes, costs, and cost-effectiveness.
Therefore, based on these results, continuing usual care is recom-
mended.
KEY WORDS: depression; disease management program; elderly;
primary care.
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T he 1-month prevalence of major depression in elderlypeople ranges from 2.0% in the community to 8.7% in
primary care.1,2 Major depression in the elderly is associated
with increased physical disability, impaired well-being, and
increased health service use and health care costs.3–7 Treat-
ment with antidepressants and psychotherapy has proven to
be efficacious in older adults with major depression.8 Never-
theless, major depression often remains unrecognized and un-
dertreated in elderly people, especially in primary care.9,10
Recognition and treatment is complicated by comorbid phys-
ical and psychiatric illnesses, life-stress, and social and finan-
cial problems.9,10 Furthermore, symptoms of depression may
be attributed to aging by both the physician and the patient.11
Screening for depression in primary care may improve
outcomes, particularly when screening is followed by adequate
treatment.12 A recent review concluded that disease manage-
ment programs can improve quality of care and outcomes for
patients with depression and that research is needed to assess
the cost-effectiveness of such programs.13
In this study, we evaluated the cost-effectiveness of a dis-
ease management program consisting of screening, diagnosis,
and treatment of major depression in elderly primary care
patients in comparison with usual care.
METHODS
Design and Setting
A cluster randomized-controlled trial was performed in 34
general practices in the Netherlands. Randomization took
place at practice level. The Medical Ethical Committee of the
VU University Medical Center in Amsterdam approved the
study protocol. The design of the study has been described
extensively.14
Patient Selection
In the participating general practices, all consecutive patients
55 years and older visiting their general practitioner (GP), were
requested by the practice assistant to complete the Geriatric
Depression Scale (GDS-15).15 In the intervention group, pa-
tients with a GDS-15 score of 5 or higher were further evalu-
ated by their GP using the mood module of the PRIMary care
Evaluation of Mental Disorders (PRIME-MD).16 In the usual
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care group, the PRIME-MD was administered by a research
assistant in order to keep the GP blind to the screening results.
Patients who were diagnosed with major depression according
to the PRIME-MD were eligible for the study. Exclusion criteria
were as follows: current use of antidepressants, current psy-
chosis, bipolar disorder, or alcohol or drugs abuse, severe so-
cial dysfunction, inability to communicate in Dutch, and
impaired cognitive functioning. General practitioners of inter-
vention patients had to agree with the diagnosis of major de-
pression and to be willing to prescribe an antidepressant.
Written informed consent was obtained from the patients both
after screening and after the diagnostic interview.
Usual Care Treatment
General practitioners in the usual care group remained blind
to the results of the screening process and did not receive any
training. Treatment of depression in the usual care group de-
pended on whether the GP recognized the patient as being de-
pressed and was not restricted in any way. Dutch GPs are
encouraged to work according to the depression guideline is-
sued by the Dutch college of GPs, which recommends that
treatment of depression primarily consists of education and
coaching. Antidepressant treatment and/or referral for psy-
chotherapy can be added, depending on the duration and se-
verity of the depressive symptoms, the limitations in daily
functioning, and the patient’s preference.17 General practi-
tioners are free to deviate from these guidelines and to organ-
ize care according to their own views.
Intervention Treatment
General practitioners in the intervention group attended a
4-hour training session that focused on the screening for, and
diagnosis and treatment of late-life depression. The treatment
offered by the GPs consisted of education and information, drug
therapy (20mg of paroxetine once daily), and supportive con-
tacts and was based on the Dutch depression guideline.17 Two
treatment phases were distinguished: an acute treatment phase
during which patients were seen every 2 weeks by their GP for a
period of 2 months, and a continuation phase during which
patients were seen monthly for a period of 4 months.
Clinical Outcome Measures
Trained interviewers, who were unaware of the allocation sta-
tus of the participating GPs, measured outcomes and resource
use during interviews at the patients’ home. Recovery from de-
pression was defined as absence of a PRIME-MD diagnosis of
major depression at 12 months. The Montgomery Asberg
Depression Rating Scale (MADRS) was used to assess chang-
es in severity of depressive symptoms during the 12 months of
the study.18 Quality of life was measured using the EuroQol
(EQ-5D).19 Quality Adjusted Life Years (QALYs) were calculat-
ed by multiplying the utility based on EuroQol scores with the
amount of time a patient spent in a particular health state.20
Transitions between health states were linearly interpolated.
All clinical outcome measures were measured shortly after the
screening (T0) and at 2 (T1), 6 (T2), and 12 (T3) months of
follow-up, with the exception of the PRIME-MD, which was not
measured at 2 months of follow-up. Because the first interview
was conducted shortly after the screening, treatment in the
intervention group had already started at T0.
Cost Measures
Costs were measured at T0, T2, and T3 from a health care
perspective using interviews. Patients were asked whether
they had visited a specific health care provider in the past 6
months and if so, how many times. Because the interviews
were conducted at the patients’ home, it was possible for pa-
tients to get a diary to check their health care utilization. All
direct health care and nonhealth care costs were considered,
because it is very hard to discern which costs are depression-
related and which are not. Of medication costs, only costs of
psychotropic medication were included in the analyses. Inter-
vention costs consisted of the total costs of the training ses-
sions for the GPs and were equally allocated to the included
intervention patients. Indirect costs of production losses were
not measured, because it was assumed that a substantial pro-
portion of the included patients had already retired. If availa-
ble, Dutch guideline prices were used to value resource
use.21,22 The cost categories and prices used are listed in the
(online Appendix). Medication costs were valued using prices
of the Royal Dutch Society for Pharmacy.23 Costs of comple-
mentary medicine visits were based on patients’ estimates. All
costs were adjusted to the year 2002 using consumer price
indices. Discounting was unnecessary, because neither costs
nor benefits were recorded beyond 12 months.
Statistical and Economic Analyses
We estimated that 68 patients in each group would be needed
(2-sided a=0.05, b=0.20) to detect moderate clinical effects
(Cohen’s d=0.50). Moderate clinical effects were considered to
be clinically relevant and convincing for GPs.14 All analyses
were intention-to-treat and limited to patients completing all
follow-up assessments. Differences between both groups in
improvement in severity of depression and QALYs gained at 12
months were tested using t tests and differences in recovery
using w2 tests.
To compare costs between the 2 groups, confidence
intervals (CIs) for the mean differences in costs were calculat-
ed using bias-corrected and accelerated bootstrapping with
2,000 replications.24 For the cost-effectiveness analyses, the
difference in total costs between the treatment groups was
compared with the difference in improvement in the MADRS
score, the difference in recovery rate based on the PRIME-MD,
and for the cost-utility analysis with the difference in QALYs.
Uncertainty around the cost-effectiveness and cost-utility ra-
tios was calculated using the bias-corrected percentile boot-
strapping method (5,000 replications).25 The bootstrapped
cost-effect pairs were plotted on a cost-effectiveness plane.
RESULTS
Of the 34 participating general practices, 18 were allocated to
the intervention group and 16 to the usual care group. There
were no significant differences between GPs in the intervention
and usual care group with regard to age, gender, and experi-
ence of GPs, and type and size of practice (data not shown).
Between June 2000 and October 2002, of 3,937 patients
screened for depressive symptoms with the GDS-15, 579
screened positive and were evaluated further using the
PRIME-MD, resulting in 178 patients with major depression
according to the PRIME-MD. Of the detected patients, 145
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(81%) gave informed consent. Sixteen otherwise eligible inter-
vention patients were not included, because their GP disa-
greed with the depression diagnosis or refused to prescribe
antidepressants. Complete follow-up was available for 125
(86%) patients (Fig. 1). Patients who were lost to follow-up were
older andmore severely depressed than patients with complete
follow-up.
Except for marital status, there were no significant differ-
ences at T0 in patient characteristics between the intervention
and the usual care group (Table 1), nor did these patient char-
acteristics differ between general practices (data not shown).
Clinical Effectiveness
Twenty-five (43%) and 32 (48%) of the patients in the inter-
vention and usual care group, respectively, had recovered
based on the PRIME-MD after 12 months. This difference in
recovery rate was not statistically significant. The differences
in improvement in severity of depressive symptoms and QALYs
gained between the 2 treatment groups were small and not
statistically significant (Table 2).
General practices randomized (n=34)
Intervention practices (n=18) Usual care practices (n=16)
Training of general 
practitioners
Patients with GDS >= 5 
(n=363)
Patients with GDS >= 5 
(n=216)
PRIME-MD + (n=95) PRIME-MD + (n=83)
Included in the study 
(n=70)
Included in the study 
(n=75)
12 withdrawals:
2 dead
4 unwilling to participate
3 too ill
1 moved
2 other/unknown
8 withdrawals:
1 dead
4 unwilling to participate
3 moved
Follow-up and analysis at 12 
months (n=58)
Follow-up and analysis at 12
months (n=67)
Screening (n=2484) Screening (n=1453)
Informed consent
PRIME-MD by GP
(n=192)
Informed consent 
PRIME-MD by RA
(n=147)
Informed consent Informed consent
FIGURE 1. Flow of participants through the trial; GDS, Geriatric Depression Scale, PRIME-MD, PRIMary care Evaluation of Mental Disorders.
Table 1. Characteristics of Patients Allocated to the Intervention or
Usual Care Group
Intervention (n=58) Usual Care (n=67)
Mean (SD) age in years 66.4 (8.6) 64.7 (7.5)
Female 38 (66) 36 (54)
Married/living together 34 (59) 52 (78)
Previous depression 49 (85) 55 (82)
Mean (SD) MADRS score 19.3 (8.7) 18.7 (7.7)
Values are numbers (percentages) of patients unless stated otherwise.
MADRS, Montgomery Asberg depression rating scale.
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Health Care Utilization
Table 3 presents the utilization of health care resources in the
2 groups over 12 months. During the study period, 95% and
94% of the intervention and usual care patients, respectively,
had at least 1 contact with their GP. Forty-six (79%) interven-
tion and only 8 (12%) usual care patients received some form of
mental health care (antidepressant medication or referral)
during the follow-up period. At all 3 measurements, interven-
tion patients were more likely to use an antidepressant. Twen-
ty-eight (48%) intervention patients received antidepressant
treatment for at least 6 months as recommended by the Dutch
depression guidelines.17
Costs
At 12 months, total direct costs were somewhat lower in the
intervention group, but this difference was not statistically
significant. Psychotropic medication costs in the intervention
group were significantly higher than in the usual care group
(Table 4). However, almost all point estimates of the differences
in costs indicated small savings. Moreover, the higher GP and
medication costs in the intervention group seem to be substi-
tuted by higher physiotherapy costs in the usual care group.
Total costs of visits to mental health care providers and
psychotropic medication in the intervention group ($243) were
higher than in the usual care group ($165), but this difference
was not statistically significant (P=.22).
Cost-Effectiveness and Cost-Utility Analyses
Figure 2 shows the cost-effectiveness planes for the interven-
tion group in comparison with the usual care group for recov-
ery, improvement in severity of depression, and QALYs gained
at 12 months. In all 3 cost-effectiveness planes, all cost-effect
pairs are located near the origin of the plane, suggesting nei-
ther large nor significant differences in costs and effects. This
shows that the intervention is not cost-effective in comparison
with usual care.
DISCUSSION
We evaluated whether a disease management program for ma-
jor depression in elderly primary care patients would be cost
effective in comparison with usual care. Although antidepres-
sant treatment rates were significantly higher in the interven-
tion group, we found no statistically significant difference in
total costs, effects, and cost-effectiveness between the 2 treat-
ment groups.
Our findings are in line with 2 randomized trials that also
found that disease management programs for elderly primary
care patients with depression had no significant effect on de-
pression severity.26,27 In contrast, Katon et al.28 found a sig-
nificant effect, accompanied by a modest and insignificant
increase in total health care costs. However, patients in that
study had access to a depression care manager, which makes
the intervention program much more intensive.
Several American observational studies reported much
higher health care costs in depressed elderly patients than
we do.4,6,28–30 These studies used computerized databases to
estimate costs, whereas our cost estimates were based on pa-
tient reports of resource use. Also, our study population was
on average about 10 years younger than the study populations
in the abovementioned studies.
There may be several explanations for the nonsignificant
results of this study. First, despite the fact that all patients
Table 2. Clinical Outcomes After 12 Months
Outcome measure Intervention (n=58) Usual Care (n=67) Intervention Versus Usual Care P Value
% (No.) Recovered (PRIME-MD) 43.1 (25) 47.8 (32) 4.7 (22.5; 13.1) .60
Mean (SD) improvement in MADRS score 7.8 (9.0) 7.2 (9.0) 0.6 (3.8; 2.6) .70
Mean (SD) QALYs gained (EQ-5D) 0.65 (0.19) 0.70 (0.21) 0.04 (0.11; 0.03) .20
Difference (95% confidence interval).
PRIME-MD, PRIMary care Evaluation of Mental Disorders, MADRS=Montgomery Asberg Depression Rating Scale, EQ-5D, EuroQol.
Table 3. Mean (Standard Deviation) Health Care Utilization of
Patients Allocated to the Intervention or Control Group During
12 Months
Type of utilization Intervention
(n=58)
Usual Care
(n=67)
Direct health care
Primary care
General practitioner (no. visits) 7.8 (5.5) 6.3 (5.5)
Dentist (no. visits) 1.3 (1.8) 0.8 (1.1)
Dietitian (no. visits) 0.3 (1.4) 0.6 (1.8)
Physical therapist (no. visits) 4.8 (14.3) 11.0 (20.6)
Social worker (no. visits) 0.2 (0.8) 0.0 (0.3)
Secondary care
Psychiatrist (no. visits) 0.0 (0.3) 0.4 (2.9)
Medical specialist (no. visits) 2.9 (3.1) 3.5 (5.1)
Hospital admission (no. d) 1.3 (3.1) 1.2 (3.1)
Hospital admission (no. d on ICU) 0 (0) 0.1 (0.3)
Psychiatric hospital admission (no. d) 0 (0) 0 (0)
Regional institute for mental welfare
(no. visits)
0.1 (0.4) 0.3 (1.4)
Psychogeriatric services (no. visits) 0 (0) 0.1 (0.6)
Rehabilitation center (no. h) 0 (0) 2.7 (19.3)
Nursing home —temporary
admission (no. d)
1.3 (9.8) 0 (0)
Nursing home—outpatients’
treatment (no. d)
0.4 (3.4) 0 (0)
Home for the elderly—temporary
admission (no. d)
0.5 (3.7) 0.2 (1.7)
Home for the elderly—outpatients’
care (no. daily periods)
0.9 (6.8) 0 (0)
Supportive care
District nurse (no. h) 0.9 (4.1) 1.0 (3.4)
Home care (no. h) 9.4 (32.9) 14.0 (38.2)
Home help (no. h) 16.1 (45.6) 10.5 (35.7)
Home for the elderly—meal supply
(no. meals)
3.1 (23.9) 0 (0)
Meal supply at home (no. meals) 1.3 (10.2) 3.9 (31.8)
Direct nonhealth care
Primary care
Alternative therapist (no. visits) 0.2 (1.2) 1.8 (8.5)
Memory training (no. contacts) 0 (0) 0.0 (0.1)
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were diagnosed as having major depression according to the
PRIME-MD, most patients detected by our screening method
were only mildly to moderately depressed according to their
MADRS scores at T0.31,32 This may arise from the fact that
screening in primary care typically leads to detection of mildly
depressed patients.33 Because patients with milder forms of
major depression are not likely to be included in trials evalu-
ating the efficacy of antidepressants, it is unclear whether
antidepressants are efficacious in these patients.34 Indeed, a
recent review concluded that antidepressants have only
moderate effects in older ambulatory patients with mild to
moderate depression.35
Another partial explanation for the nonsignificant find-
ings of this study may be the existence of a Hawthorne effect,
although this seems inevitable in this type of research. The fact
that GPs and patients knew they were participating in a study
influences their behavior and perceptions and thereby may re-
duce any differences there might have been between the treat-
ment groups. The fact that trained research assistants
interviewed study patients at home may also have contribut-
ed to the Hawthorne effect. We tried to control for a Hawthorne
effect by blinding usual care GPs to the screening results and
the research assistants to the allocation status of the GPs.
However, the Hawthorne effect may have been substantial, be-
cause, especially in the treatment of depression, attitudes, en-
vironment, time spent with patients, etc., will have an effect on
the results. Related to the Hawthorne effect is that usual care
patients frequently received GP care and physiotherapy for co-
morbid disorders. Treating comorbidity may improve out-
comes of depression as well. This may also partly explain the
relatively positive outcomes in usual care patients.
There are also 2 design aspects of our study that may have
contributed to the nonsignificant findings of our study. First,
we chose a pragmatic design, meaning that we tried to repli-
cate everyday clinical practice as much as possible to enhance
the generalizability of our findings. However, a disadvantage of
a pragmatic design is that the contrast between the treatment
groupsmay be diminished. Second, it was not possible to blind
patients included in the usual care group. Although usual care
patients were requested not to reveal to their GP that they were
participating in this study, there is a risk that some patients
informed their GP and subsequently received some kind of
treatment for depression. However, as only a few usual care
patients were prescribed antidepressants or referred to a men-
tal health care provider, this problem seems to be small.
Initiation of mental health care treatment in both the in-
tervention and the usual care group was associated with more
severe depression at baseline. Thus, GPs use severity of de-
pression as a criterion to initiate depression treatment, but
this criterion alone seems insufficient to distinguish patients
who will benefit from depression treatment from patients who
will not benefit.
General practitioners of intervention patients had to agree
with the depression diagnosis and had to be willing to pre-
scribe antidepressants, whichmay have led to selection bias in
the intervention group. In this case, it can be expected that
intervention patients have more severe depression at baseline
than usual care patients. Intervention patients were indeed
somewhat more depressed than usual care patients at base-
line, but the difference was small and not statistically signif-
icant. Therefore, we do not expect that this particular form of
selection bias was very strong in our study.
The follow-up rate of 86% is very good for studies in el-
derly depressed populations. Patients who dropped out before
the end of the study were older and more depressed than pa-
tients who completed all follow-up measurements. Moreover,
although a sufficient number of patients was included in the
study, the number of patients analyzed at 12 months was
smaller than the required sample size to detect moderate clin-
ical effects. However, the results of a missing value analysis
using the Expectation Maximization algorithm36 did not differ
from the complete case analysis (data not shown). Therefore,
we do not expect that inclusion of patients who dropped out
before the end of the study would have altered our conclu-
sions.
Our study was underpowered to detect relevant differen-
ces in costs, which is reflected in wide confidence intervals for
cost differences. This is a common problem in ‘‘piggy back’’
economic evaluations. Because the distribution of cost data is
typically heavily skewed, very large numbers of study patients
are needed to detect relevant cost differences.37 It is generally
considered unethical to increase study sizes beyond the level
needed to prove clinical effectiveness.
Another limitation to the economic evaluation presented
in this article is the manner in which cost data were collected.
In interviews, patients were asked about their health care
Table 4. Mean (Standard Deviation) Total Costs in Dollars, Differences in Mean (95% Confidence Intervals) Total Costs in Dollars, and
P valuew During Follow-up of 12mo
Intervention (n=58) Usual Care (n=67) Intervention Versus Usual Care P Value
Primary care costs 336 (375) 494 (739) 157 (313;56) .13
GP costs 170 (120) 137 (120) 33 (20;68) .12
Physiotherapy costs 115 (340) 263 (490) 148 (276;19) .05
Secondary care costs 885 (2,161) 1,021 (2,513) 136 (902;727) .75
Outpatient costs 156 (165) 189 (274) 32 (107;46) .42
Admission costs 664 (2,047) 466 (1317) 199 (418;729) .79
Supportive care costs 575 (1,289) 663 (1,482) 88 (565;414) .72
Medication costs 220 (162) 82 (333) 139 (4;407) .003
Intervention costs 106 — —
Total direct costs 2,123 (2,661) 2,259 (3,922) 136 (1,194;1,110) .82
95% confidence intervals obtained by bias-corrected and accelerated bootstrapping.
wP value obtained by applying the t distribution on the t value that was obtained during bootstrapping.
$1= h0.80.
GP, general practitioner.
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utilization over the past 6 months. Subjects in general, and
elderly subjects in particular may not be able to recall health
care utilization reliably over such a long period. This may have
introduced recall bias. Most likely, our estimates are an un-
derestimate of the true utilization rates for frequently occur-
ring resources such as visits to the GP. For more seldom
occurring resources such as hospitalizations, we expect our
estimates to be reasonably adequate.
A final limitation is that costs of production losses and
informal care giving were not measured. As the differences in
clinical outcomes and direct costs were small, we consider it
unlikely that inclusion of lost productivity costs would have
altered the results of our study. Because our study population
consisted of elderly subjects, it is probable that many subjects
received informal care. Future studies should attempt to
measure these costs.
In conclusion, this disease management program for ma-
jor depression in elderly primary care patients was not cost-
effective in comparison with usual care. There were no signif-
icant differences in depressive symptoms, quality of life, and
costs between the intervention and usual care group at 12
months. Therefore, based on these results, we recommend
continuing usual care by GPs, which mainly consists of
‘‘watchful waiting.’’ In this situation, treatment for depression
is initiated only when the GP diagnoses the patient as being
depressed. We recommend that future research focuses on im-
provement of the detection of clinically important and treatable
depression by GPs. Evidence is needed on indicators that help
GPs in determining which patients may profit from depression
treatment. Research is also needed on the (cost-) effectiveness
of treatments for depression in elderly primary care patients,
especially on the (cost-) effectiveness of treatments other than
antidepressants, such as different forms of psychotherapy.
The Dutch Health Care Insurance Board (DHCIB) financed the
trial (grant number OG 00-252).
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